DaVita Inc. (DVA) PEG Ratio: 2.54
Is DaVita Inc.’s PEG ratio high or low?
DaVita Inc.'s PEG ratio of 2.54 is 352% above its 5-year average of 0.56, near the high end of its 5-year range (0.29–2.54).
568.42% above its 12-month average of 0.38.
DVA PEG Ratio Chart
DVA Average PEG Ratio Chart
DVA Current vs Average PEG Ratio Chart
DVA PEG Ratio Metrics
PEG RATIO
2.54
PEG RATIO AVG TTM
0.38
PEG RATIO AVG 3Y
0.35
PEG RATIO AVG 5Y
0.56
PEG RATIO AVG 10Y
0.79
PEG RATIO AVG 15Y
1.03
PEG RATIO AVG 20Y
0.97
CURRENT VS TTM AVG
+568.42%
CURRENT VS 3Y AVG
+625.71%
CURRENT VS 5Y AVG
+351.96%
CURRENT VS 10Y AVG
+220.50%
CURRENT VS 15Y AVG
+147.60%
CURRENT VS 20Y AVG
+162.22%
DVA Competitors' PEG Ratio
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DaVita Inc. (DVA) | $13.40B | 2.54 | 0.38 | 0.35 | 0.56 |
| The Cooper Companies, Inc. (COO)vs › | $13.24B | N/A | 1.65 | 0.83 | 0.60 |
| Solventum Corporation (SOLV)vs › | $13.66B | 0.04 | 0.04 | 117.61 | 78.52 |
| Align Technology, Inc. (ALGN)vs › | $12.52B | 51.80 | 51.80 | 26.80 | 17.90 |
| Baxter International Inc. (BAX)vs › | $10.77B | N/A | 0.18 | 0.70 | 1.43 |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | N/A | 0.05 | 0.05 | 0.14 |
| Hologic, Inc. (HOLX)vs › | $16.97B | N/A | 0.30 | 0.22 | 1.95 |
| Charles River Laboratories International, Inc. (CRL)vs › | $9.03B | N/A | 0.04 | 0.51 | 2.58 |
| Tempus AI, Inc. (TEM)vs › | $8.35B | N/A | 0.61 | 1.49 | 1.49 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.73B | N/A | 0.10 | 0.17 | 0.14 |
Growth-Adjusted Valuation
PEG Ratio
2.54
P/E Ratio
21.0
DaVita Inc. PEG Ratio Formula & Definition
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DaVita Inc. PEG Ratio FAQ
- What is the PEG ratio for DaVita Inc. (DVA)?
- The PEG ratio for DVA stock is 2.54.
- Is DaVita Inc.'s PEG ratio high or low?
- DaVita Inc.'s PEG ratio of 2.54 is 352% above its 5-year average of 0.56, near the high end of its 5-year range (0.29–2.54).
- What is the TTM average PEG ratio for DaVita Inc. (DVA)?
- The TTM average PEG ratio for DVA stock is 0.38.
- What is the 3Y average PEG ratio for DaVita Inc. (DVA)?
- The 3Y average PEG ratio for DVA stock is 0.35.
- What is the 5Y average PEG ratio for DaVita Inc. (DVA)?
- The 5Y average PEG ratio for DVA stock is 0.56.
- What is the 10Y average PEG ratio for DaVita Inc. (DVA)?
- The 10Y average PEG ratio for DVA stock is 0.79.
- What is the 15Y average PEG ratio for DaVita Inc. (DVA)?
- The 15Y average PEG ratio for DVA stock is 1.03.
- What is the 20Y average PEG ratio for DaVita Inc. (DVA)?
- The 20Y average PEG ratio for DVA stock is 0.97.
DaVita Inc. PEG Ratio History
| DATE | PEG RATIO |
|---|---|
| 2024-12-31 | 0.30 |
| 2023-12-31 | 0.46 |
| 2021-12-31 | 0.29 |
| 2020-12-31 | 0.77 |
| 2019-12-31 | 0.99 |
| 2018-12-31 | 1.75 |
| 2016-12-31 | 0.06 |
| 2014-12-31 | 1.72 |
| 2013-12-31 | 2.55 |
| 2012-12-31 | 1.85 |
| 2011-12-31 | 0.58 |
| 2009-12-31 | 0.99 |
| 2007-12-31 | 0.55 |
| 2006-12-31 | 0.85 |
| 2004-12-31 | 0.82 |
| 2003-12-31 | 0.51 |
| 2002-12-31 | 0.34 |
| 2001-12-31 | 0.02 |
| 1998-12-31 | 2.35 |
| 1997-12-31 | 0.44 |
| 1996-12-31 | 0.44 |
Related Metrics
About DaVita Inc.
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- Javier J. Rodriguez